Cargando…

Bacillus Calmette–Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer

BACKGROUND: Bacillus Calmette–Guérin (BCG) is currently the most effective intravesical therapy for non-muscle-invasive bladder cancer (NMIBC) as it can prevent disease recurrence and progression and lower mortality. However, the response rates to BCG vary widely and are dependent on a multitude of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Fei, Liu, Ming, Zhang, Wei, Tang, Min, Zhang, Jinsong, Li, Hexin, Zou, Lihui, Zhang, Rui, Liu, Yudong, Li, Lin, Ma, Jie, Zhang, Yaqun, Chen, Meng, Xiao, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930202/ https://www.ncbi.nlm.nih.gov/pubmed/35311085 http://dx.doi.org/10.3389/fonc.2022.842182

Ejemplares similares

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis
por: Huang, Di, et al.
Publicado: (2019)

Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guérin (BCG) in non-muscular invasive bladder cancer
por: Lara Moscoloni, Luis Felipe, et al.
Publicado: (2021)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder Cancer
por: Lin, Po-Ting, et al.
Publicado: (2023)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
por: Garcia, Cindy, et al.
Publicado: (2015)

Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette–Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis
por: Zeng, Na, et al.
Publicado: (2023)

Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatment
por: Duan, Huangqi, et al.
Publicado: (2022)

Regression of the Sweet's syndrome after Bacillus Calmette-Guérin therapy: A bladder cancer case report
por: Baloglu, İbrahim Halil, et al.
Publicado: (2020)

Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
por: Kondo, Tsubasa, et al.
Publicado: (2022)

Lymphocyte-to-Monocyte Ratio (LMR) During Induction Is a Better Predictor Than Preoperative LMR in Patients Receiving Intravesical Bacillus Calmette -Guerin for Non-Muscle-Invasive Bladder Cancer
por: Li, Deng-xiong, et al.
Publicado: (2022)

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

FGFBP1 as a potential biomarker predicting bacillus Calmette–Guérin response in bladder cancer
por: Li, Fei, et al.
Publicado: (2022)

Renal Granulomatosis Post Intravesical Bacillus Calmette–Guerin Therapy for Non-muscle-invasive Bladder Cancer
por: Tran-Harding, Karen, et al.
Publicado: (2018)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
por: Suh, Jungyo, et al.
Publicado: (2021)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
por: Deng, Tuo, et al.
Publicado: (2017)

Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting
por: Yuk, Hyeong Dong, et al.
Publicado: (2019)

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies
por: Kiselyov, Alex, et al.
Publicado: (2015)

Risk factor assessment in high-risk, bacillus Calmette–Guérin-treated, non-muscle-invasive bladder cancer
por: Holz, Serge, et al.
Publicado: (2017)

Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer
por: Zhong, Wenlong, et al.
Publicado: (2020)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
por: Matsuoka, Yuki, et al.
Publicado: (2021)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Role of oral pentosan polysulfate in Bacillus Calmette–Guérin therapy in patients with non-muscle-invasive bladder cancer
por: Lee, Ho Yeon, et al.
Publicado: (2022)

Efficacy and safety of Bacillus Calmette-Guerin for bladder cancer: A protocol of systematic review
por: Zhang, Zhi-hui, et al.
Publicado: (2020)

Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies
por: Zhu, Shimiao, et al.
Publicado: (2013)

AB152. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer
por: Rachakonda, Tara, et al.
Publicado: (2017)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer
por: Damrauer, Jeffrey S., et al.
Publicado: (2021)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin
por: Hashizume, Akihito, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nnaqhmg7stinv09ppv3semqv24